{"_meta":{"attribution":"Data aggregated by pdata.world (https://pdata.world) from Polymarket, Kalshi, Manifold, Myriad, Limitless, Predict, Opinion and Gemini; CC BY 4.0; source data © each venue.","canonical_url":"https://pdata.world/events/kalshi/KXKYMR621EASI-BROADEN2W16-31DEC26","as_of":"2026-11-21T01:54:33.310588Z","docs":"https://api.pdata.world/docs","cite_as":"According to pdata.world (tracking Kalshi): \"KT-621 Week 16 EASI-75 advantage over placebo\" — 5 markets; highest \"Above 20.0 pp\" at 96% as of 2026-11-21 UTC. https://pdata.world/events/kalshi/KXKYMR621EASI-BROADEN2W16-31DEC26","source_url":"https://kalshi.com/markets/kxkymr621easi/kt-621-week-16-easi-75-advantage-over-placebo/kxkymr621easi-broaden2w16-31dec26","data_as_of":"2026-11-21T01:38:33.320706Z","full_record":"https://api.pdata.world/api/v1/events/kalshi/KXKYMR621EASI-BROADEN2W16-31DEC26","price_history":"https://api.pdata.world/api/v1/events/kalshi/KXKYMR621EASI-BROADEN2W16-31DEC26/history?range=7d&limit=20"},"kind":"live","venue":"Kalshi","source":"kalshi","id":"KXKYMR621EASI-BROADEN2W16-31DEC26","title":"KT-621 Week 16 EASI-75 advantage over placebo","status":"open","categories":["Finance"],"closes_at":"2027-01-01T04:59:59Z","outcomes_are":"independent markets, each resolving on its own","volume_24h":6486.56,"volume_total":6486.56,"volume_unit":"contracts, as Kalshi reports them","outcomes_total":5,"outcomes":[{"name":"Above 40.0 pp","probability":0.3,"change_24h":0.3,"volume_24h":2798.37,"market_id":"KXKYMR621EASI-BROADEN2W16-31DEC26-T40P0"},{"name":"Above 25.0 pp","probability":0.96,"change_24h":0.96,"volume_24h":2067.31,"market_id":"KXKYMR621EASI-BROADEN2W16-31DEC26-T25P0"},{"name":"Above 20.0 pp","probability":0.96,"change_24h":0.96,"volume_24h":1070.88,"market_id":"KXKYMR621EASI-BROADEN2W16-31DEC26-T20P0"},{"name":"Above 30.0 pp","probability":0.55,"change_24h":0.55,"volume_24h":550.0,"market_id":"KXKYMR621EASI-BROADEN2W16-31DEC26-T30P0"},{"name":"Above 35.0 pp","volume_24h":0.0,"market_id":"KXKYMR621EASI-BROADEN2W16-31DEC26-T35P0"}],"rules":"If the difference between KT-621’s and placebo’s Week 16 EASI-75 response rates in the Phase 2b BROADEN2 trial (NCT07217015), as reported in the Initial Disclosure on or before Dec 31, 2026 at 11:59:59 PM ET, is above 40.0 percentage points, then the market resolves to Yes.\n\n---\n\nThe trial is the Phase 2b BROADEN2 trial (NCT07217015). The endpoint is Week 16 EASI-75. The qualifying Initial Disclosure must occur on or before Dec 31, 2026 at 11:59:59 PM ET. AppliedXL is the settlement source. The value is the drug’s reported responder percentage minus placebo’s reported responder percentage, not a sponsor-reported adjusted treatment difference or p-value. Where no dose or treatment arm is specified for KT-621, use the largest difference among individually reported active arms in the Initial Disclosure; pooled arms and combination regimens are excluded unless explicitly specified. Later-disclosed arms do not count. The sponsor-designated primary analysis governs; otherwise use missing-as-nonresponder analysis across the full randomized/full analysis population, then the largest reported population. Use reported percentage precision without rounding the difference. If only counts are reported, calculate each response rate and round it to one decimal place as specified in the rulebook; reported percentages govern over inconsistent counts. A qualitative success announcement, interim analysis, subgroup/post-hoc analysis, open-label extension, or disclosure containing only a treatment difference does not qualify. No Initial Disclosure by the deadline resolves every threshold No. If an initial publication has a material error and no reliable data is available by expiration, the rulebook’s last-fair-price provision applies. No No-data strike is included. Expiration moves earlier under Rule 7.2 when the Initial Disclosure occurs; latest expiration and last trading time are 10:00 AM ET seven calendar days after the disclosure deadline date. Full TRIALEFFICACY terms govern corrections and all other contingencies.","rules_apply_to":"the first outcome listed; each other outcome has its own text, in the full record"}